Lung cancer: diagnosis and management

Treatment pathways

We have produced treatment pathways bringing together NICE recommended treatment options from this guideline and relevant technology appraisal guidance on advanced non-small-cell lung cancer (squamous and non-squamous). The treatment pathways cover the recommended treatment options at each decision point.

These are available to view as individual pathways (linked below), or grouped together in a single interactive PDF of all treatment pathways for squamous and non-squamous advanced non-small-cell lung cancer.

We have also produced fully accessible summaries of the treatment pathways.

Squamous non-small-cell lung cancer

No targetable mutations, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%

No targetable mutations, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher

RET fusion positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

RET fusion positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

NTRK fusion positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with NTRK fusion positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with NTRK fusion positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

NTRK fusion positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with NTRK fusion positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with NTRK fusion positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

KRAS G12C positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

KRAS G12C positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

METex14 skipping alteration, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 less than 50%

METex14 skipping alteration, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration squamous non-small-cell lung cancer, with PD-L1 50% or higher

BRAF V600 positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 less than 50%

BRAF V600 positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive squamous non-small-cell lung cancer, with PD-L1 50% or higher

Non-squamous non-small-cell lung cancer

No targetable mutations, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 less than 50%

No targetable mutations, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with non-squamous non-small-cell lung cancer, with no targetable mutations and PD-L1 50% or higher

RET fusion positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

RET fusion positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with RET fusion positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

NTRK fusion positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with NTRK fusion positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with NTRK fusion positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

NTRK fusion positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with NTRK fusion positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with NTRK fusion positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

KRAS G12C positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

KRAS G12C positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with KRAS G12C positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

METex14 skipping alteration, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

METex14 skipping alteration, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with METex14 skipping alteration non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

BRAF V600 positive, PD-L1 less than 50%

Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 less than 50%

BRAF V600 positive, PD-L1 50% or higher

Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

Fully accessible summary of Systemic anti-cancer therapy: treatment options for people with BRAF V600 positive non-squamous non-small-cell lung cancer, with PD-L1 50% or higher

ROS-1 positive

Systemic anti-cancer therapy: treatment options for people with ROS-1 positive non-squamous non-small-cell lung cancer

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with ROS-1 positive non-squamous non-small-cell lung cancer

EGFR-TK positive

Systemic anti-cancer therapy: treatment options for people with EGFR-TK positive non-squamous non-small-cell lung cancer

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with EGFR-TK positive non-squamous non-small-cell lung cancer

ALK positive

Systemic anti-cancer therapy: treatment options for people with ALK positive non-squamous non-small-cell lung cancer

Fully accessible summary of systemic anti-cancer therapy: treatment options for people with ALK positive non-squamous non-small-cell lung cancer